Updated:
Alzheimer's Research UK
Founded in 1992, Alzheimer's Research UK has become the UK's preeminent force in dementia research funding under the leadership of Chief Executive Hilary...
Alzheimer's Research UK
Founded in 1992, Alzheimer's Research UK has become the UK's preeminent force in dementia research funding under the leadership of Chief Executive Hilary Evans and President Lord David Cameron. Its mission is to accelerate scientific discovery across all forms of dementia, channeling capital into lab-based research and clinical-stage programs. The organization maintains its headquarters at Granta Park in Cambridge, a hub for the UK's life sciences sector. The charity deploys its endowment across a targeted pipeline covering early-stage, seed, and expansion-stage initiatives. Its funding model blends direct research grants, academic partnerships, and a strategic co-investment approach exemplified by the Dementia Frontiers Fund, launched in partnership with Gates Ventures. This vehicle is designed to back high-risk, high-reward translational science. The organization has also co-founded the UK Dementia Research Institute (UKDRI), a multi-center national research program. Its investment portfolio includes traditional long-term holdings and a cryptocurrency donation portfolio. Geographic deployment is concentrated in the United Kingdom, though its research partnerships extend findings globally. Alzheimer's Research UK operates with a lean professional team anchored by Evans and a board chaired by Gavin Patterson, former CEO of BT Group. Its endowment, estimated at £46.7 million (Altss estimate), is augmented by innovative fundraising channels — including a strategic partnership with Omaze and the Pioneers' Circle, a network for high-level philanthropists. The charity is a member of the Association of Medical Research Charities (AMRC), adhering to rigorous peer-reviewed funding standards. Lord Cameron's presidency adds political and convening power, while Sir Jackie Stewart's Race Against Dementia provides a complementary, Formula 1-inspired urgency to research funding. The organization's structural differentiator is its hybrid model, operating as a charitable foundation but investing with the posture of a specialist venture capital fund. By directly seeding translational research and co-managing specialized vehicles like the Dementia Frontiers Fund, it performs due diligence and takes concentrated bets on scientific teams, rather than purely passive grant-making. This architecture bridges the gap between academic discovery and clinical application, creating a focused conduit for investment into a single disease area.
General information
Firm type
Endowment / Foundation
Year founded
1992
AUM
Undisclosed
Location
Region
Europe
Country
United Kingdom
City
Cambridge
Corporate office
3 Riverside, Granta Park, Cambridge, CB21 6AD, United Kingdom
Principals
Hilary Evans
Chief Executive Officer
The Rt Hon the Lord Cameron
President
Gavin Patterson
Chair of the Board of Trustees
Sector focus
Frequently asked questions
Who runs investment and grant-making decisions at Alzheimer's Research UK?
Chief Executive Hilary Evans leads the executive team responsible for the charity's strategic direction and capital deployment. The Board of Trustees, chaired by Gavin Patterson, provides governance over major funding commitments. Scientific grant decisions are guided by an expert advisory panel, ensuring funding adheres to the rigorous peer-review standards set by the Association of Medical Research Charities (AMRC).
How does Alzheimer's Research UK source proprietary research opportunities?
The charity sources opportunities primarily through its deep academic networks and its role as a co-founder of the UK Dementia Research Institute (UKDRI). It also identifies translational science prospects via the Dementia Frontiers Fund, a partnership with Gates Ventures. Its internal scientific team proactively scans the UK's university labs for early-stage projects, a model that functions as a proprietary research pipeline.
Does Alzheimer's Research UK participate in fund commitments or only direct research grants?
Alzheimer's Research UK operates a mixed deployment model. It makes direct research grants to academic institutions and also participates in specialized fund commitments. The most prominent example is its partnership in the Dementia Frontiers Fund, where it acts as a co-investor alongside Gates Ventures to back high-risk translational science, a structure that mirrors a venture fund.
What role does Lord David Cameron play at the organization?
The Rt Hon the Lord Cameron serves as President of Alzheimer's Research UK. In this role, he acts as a high-level ambassador, leveraging his political and diplomatic status to advocate for increased dementia research funding and policy focus, both within the UK and internationally. He does not manage day-to-day operations or investment decisions.
Is Alzheimer's Research UK structured as a typical endowed foundation?
No. While it is a charitable foundation with a long-term investment portfolio, its operational model is distinct. It functions more like a disease-focused venture capital firm by actively partnering with entities like Gates Ventures on specialized funds and co-founding national research institutes. Its direct role in shaping and managing research programs differentiates it from a purely passive endowment.
Which sectors does Alzheimer's Research UK explicitly avoid?
The charity's exclusive mandate is to fund research into the causes, treatment, diagnosis, and prevention of dementia. It does not fund general healthcare services, unrelated neurological conditions, or non-scientific initiatives. Its negative screen is implicit: any project outside of dementia research is not considered for capital deployment.
How are philanthropic structures like the Pioneers' Circle separated from research grant funding?
The Pioneers' Circle is a donor network for high-level philanthropists and business leaders. Funds raised through this network and partners like Omaze are aggregated into the charity's general fund. The scientific advisory process then allocates capital to research based purely on scientific merit and the AMRC's peer-review principles, creating a separation between fundraising relationships and grant-making decisions.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: